ArticleScientific reports2025
Identification and in silico evaluation of natural compounds from Annona muricata (soursop) leaves for colon cancer treatment.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Annona muricata (soursop), a traditional medicinal plant renowned for its anticancer properties due to annonaceous acetogenins, was investigated to identify potent phytochemicals targeting colon cancer. Considering the significant role of genetic mutations such as MLH1 in colorectal carcinogenesis, this study aimed to explore natural compounds with therapeutic potential. Gas chromatography-mass spectrometry (GC-MS) analysis identified 52 phytochemicals from A. muricata, which were filtered through Lipinski's rule of five to select 14 drug-like candidates. Molecular docking using PyRx prioritized seven compounds-alpha-tocopherol, 4,6-O-benzylidene-D-galactose, methyl 3-(3,5-di-tert-butyl-4-hydroxyphenyl)propionate, (5 S)-2(3 H)-furanone dihydro-5-methyl-5-phenyl-, (2R,3R,4aR,5 S,8aS)-2-hydroxy-4a,5-dimethyl-3-(prop-1-en-2-yl)octahydronaphthalen-1(2 H)-one, naphthalene 1,2,3,4,5,6-hexahydro-4,7-dimethyl-1-(1-methylethyl)-, and isobutyl phenylacetate. Pharmacokinetic properties (ADMET) were evaluated, and electronic characteristics were analyzed via density functional theory (DFT). Molecular dynamics (MD) simulations over 100 ns confirmed the stability of drug-protein complexes through RMSD, radius of gyration (Rg), SASA, RMSF, and hydrogen bonding patterns. Results demonstrated that these phytochemicals exhibited superior binding affinities compared to standard therapy, 5-fluorouracil, with alpha-tocopherol notably outperforming it. ADMET analyses verified favorable pharmacokinetics, indicating non-toxicity and non-carcinogenicity. Stability assessments showed consistent parameters throughout the simulation. Overall, the prioritized phytochemicals from A. muricata, especially alpha-tocopherol, exhibit significant anticancer potential and stability, supporting further experimental validation and development as therapeutic agents for colon cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.